GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (HNE) inhibitor with IC50 value of 22 nM and Ki value of 0.31 nM.
体外研究
GW-311616 (150 μM; 48 hours) markedly suppresses NE activity in U937 and K562 cells lines.
GW-311616 (20-320 μM; 48 hours; U937 cells) treatment inhibits proliferation and induces apoptosis in leukemia cells.
GW-311616 (150 μM; U937 cells) treatment can increase the protein expression levels of Bax and decrease the expression of Bcl-2.
Cell Viability Assay
Cell Line:
U937 and K562 cells
Concentration:
150 μM
Incubation Time:
48 hours
Result:
Markedly suppressed NE activity.
Apoptosis Analysis
Cell Line:
U937 cells
Concentration:
20 μM, 40 μM, 80 μM, 160 μM, 320 μM
Incubation Time:
48 hours
Result:
The rate of apoptosis was enhanced.
Western Blot Analysis
Cell Line:
U937 cells
Concentration:
150 μM
Incubation Time:
48 hours
Result:
Increased the protein expression levels of Bax and decreased the expression of Bcl-2.
体内研究
GW-311616 (2 mg/kg; oral administration) rapidly abolishes the circulation of neutrophil elastase (NE) in dogs, while >90% inhibition is maintained for 4 days. This prolonged effect is independent to be due to penetration of neutrophils in bone marrow by orally administrated GW-311616. GW-311616 has moderate terminal elimination half-life (t1/2) of 1.1 hours and 1.5 hours for dog (2 mg/kg, oral), rat (2 mg/kg, oral), respectively.
Animal Model:
Dogs (9-month-old)
Dosage:
0.22 mg/kg, 0.66 mg/kg and 2 mg/kg (Pharmacokinetic study)
Administration:
Oral administration
Result:
At 0.22 mg/kg, greater than 50% inhibition of elastase was achieved 6 hours after dosing, with activity returning towards control values. Single oral dose of 2 mg/kg rapidly abolished circulating enzyme activity, and greater than 90% inhibition was maintained for 4 days.
分子式
C19H31N3O4S
分子量
397.53
CAS号
198062-54-3
运输条件
Room temperature in continental US; may vary elsewhere.